Poseida Therapeutics, Inc. Common Stock

PSTX

시가총액 US$9.26억

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Poseida Therapeutics, Inc. (NASDAQ: PSTX) to Roche Holdings, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash upon achievement of specific milestones, is fair to Poseida shareholders. Halper Sadeh encourages Poseida shareholders to click here to learn more about their le.

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Additional new profiling of patient responses from the optimized lymphodepletion arm (Arm C) show consistent P-BCMA-ALLO1 cellular expansion and persistence across subgroups New preclinical data supports P-CD19CD20-ALLO1's strong anti-cancer profile and the ongoing Phase 1 clinical trial Case study demonstrates reactivation of an autologous Poseida CAR-T therapy with a T-cell engager in patient with relapsed multiple myeloma, highlighting potential of TSCM-based CAR-T therapies to deliver a strong anti-myeloma response with long-term remission and CAR-T cell persistence SAN DIEGO , Dec. 9, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today will highlight interim clinical data from its Phase 1 trial of P-BCMA-ALLO1 in patients with relapsed/refractory multiple myeloma (RRMM), including new profiling of patient responses from Arm C, an optimized lymphodepletion arm. The P-BCMA-ALLO1 data are being presented, along with two additional Company poster presentations covering new preclinical data for P-CD19CD20-ALLO1 and a patient case study demonstrating the reactivation of a Poseida autologous CAR-T therapy with a T-cell engager, at the 66th ASH Annual Meeting and Exposition being held in San Diego on December 7-10, 2024.

From a technical perspective, Poseida Therapeutics, Inc. (PSTX) is looking like an interesting pick, as it just reached a key level of support. PSTX's 50-day simple moving average crossed above its 200-day simple moving average, which is known as a "golden cross" in the trading world.

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Poseida Therapeutics, Inc. (NasdaqGS: PSTX) to Roche Holdings, Inc. Under the terms of the proposed transaction, shareholders of Poseida will receive $9.00 in cash plus a non-tradeable contingent value right to receive certain contingent payments of up to an aggregate of $4.00 per share in cash (upon achieveme.

The consensus price target hints at a 49.3% upside potential for Poseida Therapeutics (PSTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Poseida Therapeutics (PSTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

NEW YORK , Nov. 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Poseida Therapeutics, Inc. (NASDAQ: PSTX ), relating to the proposed merger with Roche Holdings, Inc. Under the terms of the agreement, Poseida Therapeutics will be acquired at a price of $9.00 per share in cash at closing, plus a non-tradeable CVR to receive certain contingent payments of up to an aggregate of $4.00 per share.

Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Roche's offer values each share of Poseida Therapeutics at $9.0 that translates to a more than 200% premium on their previous close.

Poseida Therapeutics, a cell therapy company, is being acquired by Roche in a $1.5 billion deal.